期刊
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
卷 25, 期 1-2, 页码 41-49出版社
WALTER DE GRUYTER GMBH
DOI: 10.1515/jpem-2011-0469
关键词
adiponectin; high-sensitivity C-reactive protein; interleukin 6; metformin; obesity; tumor necrosis factor alpha
Objective: To compare serum concentrations of inflammatory cytokines, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), adiponectin, and tumor necrosis factor alpha (TNF alpha), before and after 3 months treatment with metformin in obese adolescents with insulin resistance (IR). Design and subjects: This was a randomized, double-blinded, clinical trial of two groups of obese adolescents with IR, aged 9-18 years: a placebo group (n = 14) and a metformin group (n = 12) who received 500 mg metformin every 12 h for 3 months. Anthropometric and biochemical (metabolic and inflammatory cytokines) assessments were compared at the beginning and end of treatment. Results: After 3 months of treatment, body mass index (kg/m(2)) was reduced in both groups: placebo group (32.82+/-6.37-32.10+/-6.52; p = 0.011) and metformin group (33.44+/-5.82-32.71+/-5.77; p = 0.015). Serum fasting insulin concentrations (pmol/L) increased in the placebo group (189.45+/112.64-266.06+/167.79; p = 0.01) and showed a slight decrease in the metformin group (256.82+/113.89-229.25+/-86.53; p = 0.64). Adiponectin concentrations (mu g/mL) decreased in the placebo group (13.17+/7.31-5.65+/6.69; p = 0.02), while these remained stable in the metformin group (8.57+/3.98-7.86+/6.23; p = 0.64). In the metformin group, significant reductions were found in the variances of serum TNF alpha concentrations (p = 0.006; Levene test). Conclusion: These results suggest that treating obese adolescents with IR using metformin for 3 months is an option for patients without response to traditional lifestyle change because metformin improves inflammatory activity, which is an etiological factor in cardiovascular disease development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据